Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device⁎⁎Thoratec Corporation, Pleasanton, Calif.

Slaughter, Mark S.; Tsui, Steven; El‐Banayosy, Aly; Sun, Benjamin; Kormos, Robert L.; Mueller, Dale K.; Massey, H. Todd; Icenogle, Timothy B.; Farrar, David J.; Hill, J. Donald

doi:10.1016/j.jtcvs.2006.11.050

Cited by 126 publications

(56 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although approved only for short-term use, there are reports of more prolonged support with the CentriMag device. 265 There are no randomized trials using the CentriMag, but small case series have reported modest success. 266,267 The Abiomed (Abiomed, Inc, Danvers, MA) ventricular assist system can also be used as a univentricular or biventricular device.…”

Section: Other Mechanical Therapiesmentioning

confidence: 99%

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

Diepen¹,

Katz²,

Albert³

et al. 2017

Circulation

1,343

1,165

View full text Add to dashboard Cite

Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite improving survival in recent years, patient morbidity and mortality remain high, and there are few evidence-based therapeutic interventions known to clearly improve patient outcomes. This scientific statement on cardiogenic shock summarizes the epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, surgical, mechanical circulatory support, and palliative care practices; advocates for the development of regionalized systems of care; and outlines future research priorities. Cardiogenic shock (CS) is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypoxia.1,2 Acute myocardial infarction (MI) with left ventricular (LV) dysfunction remains the most frequent cause of CS. 1,3 Advances in reperfusion therapy have been associated with improvements in survival, but significant regional disparities in evidence-based care have been reported, and in-hospital mortality remains high (27%-51%).1,4-9 Management recommendations are distributed between disease-specific statements and guidelines, and a dedicated and comprehensive clinical resource in this area is lacking. Thus, consolidating the evidence to define contemporary best medical and surgical CS practices for both MI-associated CS and other types of CS may be an important step in knowledge translation to help attenuate disparities in evidence-based care.Regional systems of care coupled with treatment algorithms have improved survival in high-acuity time-sensitive conditions such as MI, out-of-hospital cardiac arrest (OHCA), and trauma.10-12 Applying a similar framework to CS management may lead to similar improvements in survival, and CS systems of care are emerging within existing regional cardiovascular emergency care networks; however, guidance from a national expert group on structure and systems of care has not been available. 13,14 Accordingly, the purposes of this American Heart Association (AHA) scientific statement on CS are to summarize our contemporary understanding of the epidemiology, pathophysiology, and in-hospital best care practices into a single clinical resource document; to suggest a stepwise management algorithm that integrates medical, surgical, and mechanical circulatory support (MCS) therapies; and to propose a Mission: Lifelinesupported pathway for the development of integrated regionalized CS systems of care. DEFINITION OF CSAcute cardiac hemodynamic instability may result from disorders that impair function of the myocardium, valves, conduction system, or pericardium, either in isolation HISTORICAL PERSPECTIVESBefore the routine use of early revascularization, MIassociated CS had an in-hospital mortality exceeding 80%. A registry trial of 250 patients with acute MI described the association between bedside physical examination (Killip classification) for the as...

show abstract

Section: Other Mechanical Therapiesmentioning

confidence: 99%

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

Diepen¹,

Katz²,

Albert³

et al. 2017

Circulation

1,343

1,165

View full text Add to dashboard Cite

show abstract

“…Nonetheless, the number of nonpulsatile-flow devices has been increasing in clinical applications since those devices are usually smaller and produce less frequent bleeding and infections. 13 However, the loss of pulsatility is unphysiologic and interferes with the integrity of the circulatory system. Different studies show continuous flow to have a substantial impact on the aortic and arterial walls, considering the thinning of the medial layer and volume ratio of smooth muscle cells.…”

Section: Discussionmentioning

confidence: 99%

Review of Recent Results using Computational Fluid Dynamics Simulations in Patients Receiving Mechanical Assist Devices for End-Stage Heart Failure

Farag¹,

Karmonik²,

Rengier³

et al. 2014

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

“…[14][15][16] Progress in developing pediatric devices has been much slower because of the proportionately greater variation in size among children. Other reasons for the slow progress include biologic differences in the response to anticoagulant medicines, low levels of interest in the medical industry, and in particular, the size constraints in very small babies.…”

Section: Discussionmentioning

confidence: 99%

Prospective Trial of a Pediatric Ventricular Assist Device

2012

N Engl J Med

View full text Add to dashboard Cite

Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device⁎⁎Thoratec Corporation, Pleasanton, Calif.

Cited by 126 publications

References 23 publications

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

Review of Recent Results using Computational Fluid Dynamics Simulations in Patients Receiving Mechanical Assist Devices for End-Stage Heart Failure

Prospective Trial of a Pediatric Ventricular Assist Device

Contact Info

Product

Resources

About